TY - JOUR
T1 - Guillain-BarrÉ syndrome subtype diagnosis
T2 - A prospective multicentric European study
AU - Van den Bergh, Peter Y.K.
AU - Piéret, Françoise
AU - Woodard, John L.
AU - Attarian, Shahram
AU - Grapperon, Aude Marie
AU - Nicolas, Guillaume
AU - Brisset, Marion
AU - Cassereau, Julien
AU - Rajabally, Yusuf A.
AU - Van Parijs, Vinciane
AU - Verougstraete, Donatienne
AU - Jacquerye, Philippe
AU - Raymackers, Jean Marc
AU - Redant, Céline
AU - Michel, Claure
AU - Delmont, Emilien
N1 - Publisher Copyright:
© 2018 Wiley Periodicals, Inc.
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Introduction: There is uncertainty as to whether the Guillain-Barré syndrome (GBS) subtypes, acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and acute motor axonal neuropathy (AMAN), can be diagnosed electrophysiologically. Methods: We prospectively included 58 GBS patients. Electrodiagnostic testing (EDX) was performed at means of 5 and 33 days after disease onset. Two traditional and one recent criteria sets were used to classify studies as demyelinating or axonal. Results were correlated with anti-ganglioside antibodies and reversible conduction failure (RCF). Results: No classification shifts were observed, but more patients were classified as axonal with recent criteria. RCF and anti-ganglioside antibodies were present in both subtypes, more frequently in the axonal subtype. Discussion: Serial EDX has no effect on GBS subtype proportions. The absence of exclusive correlation with RCF and anti-ganglioside antibodies may challenge the concept of demyelinating and axonal GBS subtypes based upon electrophysiological criteria. Frequent RCF indicates that nodal/paranodal alterations may represent the main pathophysiology. Muscle Nerve 58: 23–28, 2018.
AB - Introduction: There is uncertainty as to whether the Guillain-Barré syndrome (GBS) subtypes, acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and acute motor axonal neuropathy (AMAN), can be diagnosed electrophysiologically. Methods: We prospectively included 58 GBS patients. Electrodiagnostic testing (EDX) was performed at means of 5 and 33 days after disease onset. Two traditional and one recent criteria sets were used to classify studies as demyelinating or axonal. Results were correlated with anti-ganglioside antibodies and reversible conduction failure (RCF). Results: No classification shifts were observed, but more patients were classified as axonal with recent criteria. RCF and anti-ganglioside antibodies were present in both subtypes, more frequently in the axonal subtype. Discussion: Serial EDX has no effect on GBS subtype proportions. The absence of exclusive correlation with RCF and anti-ganglioside antibodies may challenge the concept of demyelinating and axonal GBS subtypes based upon electrophysiological criteria. Frequent RCF indicates that nodal/paranodal alterations may represent the main pathophysiology. Muscle Nerve 58: 23–28, 2018.
KW - anti-ganglioside antibodies
KW - electrophysiological subtypes
KW - Guillain-Barré syndrome
KW - nerve conduction studies
KW - nodopathy/paranodopathy
KW - reversible conduction failure
UR - http://www.scopus.com/inward/record.url?scp=85041308406&partnerID=8YFLogxK
UR - https://onlinelibrary.wiley.com/doi/10.1002/mus.26056
U2 - 10.1002/mus.26056
DO - 10.1002/mus.26056
M3 - Article
AN - SCOPUS:85041308406
SN - 0148-639X
VL - 58
SP - 23
EP - 28
JO - Muscle and Nerve
JF - Muscle and Nerve
IS - 1
ER -